<DOC>
	<DOCNO>NCT01118793</DOCNO>
	<brief_summary>This Scripps pilot study effect high clopidogrel maintenance dose relationship cytochrome P450 2C19 polymorphism status [ STSI/CTSA ] .</brief_summary>
	<brief_title>Pilot Study Effect High Clopidogrel Maintenance Dosing</brief_title>
	<detailed_description>When add aspirin , clopidogrel routine dose 75 mg daily reduces incidence thrombotic vascular adverse event patient acute coronary syndrome undergo percutaneous intervention ( PCI ) . The observation many patient less expected platelet inhibition clopidogrel give rise concept clopidogrel resistance . Clopidogrel resistance associate increased adverse event stent thrombosis , post-stent ischemic event periprocedural myocardial infarction . Some patient overcome resistance increase dose clopidogrel . A high maintenance dose ( 150 mg daily ) patient undergo PCI result superior platelet inhibition may reduce cardiovascular event . Clopidogrel thienopyridine prodrug , convert active metabolite several enzyme P450 family , include CYP2C19 . The loss-of-function CYP2C19*2 ( 681 G &gt; A ) single nucleotide polymorphism ( SNP ) , occur either hetero- homozygous allele , reduce conversion clopidogrel active metabolite . Two recent study show association CYP2C19*2 polymorphism lack platelet inhibition clopidogrel . These study include healthy volunteer patient undergo elective PCI demonstrate prevalence CYP2C19*2 allele 25-30 % . Platelet inhibition affect clopidogrel carry CYP2C19*2 polymorphism . Our hypothesis following : Patients carrier loss-of-function CYP2C19*2 allele ( heterozygous 1*/2* homozygous 2*/2* ) decrease platelet inhibition clopidogrel overcome increase maintenance dose 75 mg 150 mg daily . The specific aim include evaluation anti-platelet response high maintenance dose clopidogrel ( 150 mg /daily ) patient resistant usual dose ( 75 mg/daily ) either carrier non-carriers CYP2C19*2 allele . The study design single center , prospective , observational pilot study . We screen enroll patient follow Scripps Clinic chronic clopidogrel therapy . All patient eligible . A blood sample collect perform DNA extraction genotyping CYP2C19*2 polymorphism . Platelet function assay perform use VerifyNow point-of-care assay . We recruit 60 patient high platelet reactivity ( PRU &gt; 230 ) : 30 wild-types ( normal ) 30 carrier ( heterozygous homozygous ) CYP2C19*2 polymorphism . These patient give 150 mg clopidogrel 1 week , time platelet assay repeat . At time , patient counsel study physician regard potential risk benefit continue receive 150 mg clopidogrel per day versus return FDA approve dose 75 mg daily . The immediate objective evaluate possibility overcome clopidogrel resistance carrier CYP2C19*2 high maintenance dose . The long term objective improve patient care outcomes use personalize medicine base individual 's genotype .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<criteria>Males nonpregnant female age 1885 . Patients able give inform write consent . Patients clopidogrel â‰¥ 7 day . Participation study experimental therapy device within prior 30 day . Pregnant woman woman childbearing potential use acceptable method contraception proven negative pregnancy test result . Inability comply aspect protocol . History bleed diathesis evidence active abnormal bleeding within previous 90 day . Severe hypertension ( systolic blood pressure &gt; 200 mm Hg diastolic blood pressure &gt; 110 mm Hg ) adequately control antihypertensive therapy . Major surgery within precede 6 week . History stroke within 30 day history hemorrhagic stroke . History intracranial neoplasm . Current plan administration another parenteral GP IIbIIIa inhibitor within 7 day enrollment . Known hypersensitivity component product . Unstable angina dynamic ST T wave change within 48 hour enrollment . Administration LMWH within 8 hour prior enrollment UFH within 60 minute unless PPT &lt; 50 sec ACT &lt; 150 sec . On chronic anticoagulation ( i.e . Coumadin ) . Hemoglobin &lt; 10 g/dL . Hematocrit &lt; 30 % . Platelet count &lt; 100,000 mcL .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2010</verification_date>
</DOC>